Wave Life Sciences (WVE) Cash from Investing Activities (2014 - 2026)
Wave Life Sciences' (WVE) quarterly Cash from Investing Activities came in at -$123.5 million in Q2 2026, down 40244.44% YoY from N/an in Q2 2025, and down 28085.84% on a QoQ basis from -$438000.0 in Q1 2026.
Powered by 
Analysis
Wave Life Sciences (WVE) Cash from Investing Activities (2014 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 13 years of Cash from Investing Activities data on file, last reported at -$123.5 million in Q2 2026.
- Quarterly Cash from Investing Activities fell 40244.44% year-over-year to -$123.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$124.1 million (down 13106.28% YoY) and the FY2025 annual result came in at -$718000.0, up 23.45% from the prior year.
- Cash from Investing Activities slipped to -$123.5 million in Q2 2026, from -$438000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $24.8 million in Q4 2022 to a low of -$123.5 million in Q2 2026.
- A 5-year average of -$7.1 million and a median of -$277000.0 in 2025 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 165700.0% in 2022, down 46388.89% in 2022.
- Tracing WVE's Cash from Investing Activities over 5 years: stood at $24.8 million in 2022, then sank by 101.43% to -$356000.0 in 2023, then soared by 75.84% to -$86000.0 in 2024, then soared by 101.16% to $1000.0 in 2025, then plunged by 12345500.0% to -$123.5 million in 2026.
- The last three Cash from Investing Activities figures came in at -$123.5 million (Q2 2026), -$438000.0 (Q1 2026), and $1000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Wave Life Sciences | 994.54 Mn | 626.53 Mn | - | -123.45 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -123.45 Mn |
| Mar 31, 2026 | -438,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | -248,000.00 |
| Jun 30, 2025 | -306,000.00 |
| Mar 31, 2025 | -165,000.00 |
| Dec 31, 2024 | -86,000.00 |
| Sep 30, 2024 | -383,000.00 |
| Jun 30, 2024 | -52,000.00 |
| Mar 31, 2024 | -417,000.00 |
| Dec 31, 2023 | -356,000.00 |
| Sep 30, 2023 | -198,000.00 |
| Jun 30, 2023 | -72,000.00 |
| Mar 31, 2023 | -489,000.00 |
| Dec 31, 2022 | 24.84 Mn |
| Sep 30, 2022 | -501,000.00 |
| Jun 30, 2022 | 24.61 Mn |
| Mar 31, 2022 | -50.21 Mn |
| Dec 31, 2021 | -15,000.00 |
| Sep 30, 2021 | -98,000.00 |